News

A nanoparticle-based wireless deep brain stimulation (DBS) system restored the activity of degenerating neurons and increased dopamine release in cellular and mouse models of Parkinson’s disease, a study shows. The technology also eliminated alpha-synuclein clumps, a hallmark feature of the disease, and improved the animals’ motor abilities. According…

C2N Diagnostics and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) are teaming up to study how Parkinson’s disease and similar neurodegenerative conditions overlap with Alzheimer’s disease. With a grant in the amount of more than $1.5 million from MJFF, researchers at C2N will identify and…

A mobile application that detects a person’s natural walking pace and provides real-time, beat-synchronized music for at-home rehabilitation improved walking in Parkinson’s disease patients, both during daily activities and in tests without music cues, a study found. The study, “Gait ecological assessment in persons with Parkinson’s disease engaged…

Blood levels of the fibronectin protein could be used as a predictor of disability in people with Parkinson’s disease, according to a recent study. Lower levels of the protein, referred to as plasma fibronectin (pFN), associated with a shorter time to reaching the start of a disability milestone like…

Hearing loss may be a risk factor for developing Parkinson’s disease, or may be an early warning sign of the neurodegenerative condition, according to a new study from the U.K. Specifically, the study found that for every 10 decibels of hearing impairment, the risk of developing Parkinson’s increased by…

The Michael J. Fox Foundation (MJFF) has launched this year’s “Parkinson’s IQ + You,” a series of in-person events to help patients and care partners effectively navigate the challenges of Parkinson’s disease. Launched in 2019, the free event series seeks to educate people about the disease, including…

A Phase 2 clinical trial of AB-1005, AskBio’s gene therapy for Parkinson’s disease, has randomly assigned its first participants to different treatment groups, the company has announced. Called REGENERATE-PD (NCT06285643), the trial is expected to enroll about 87 adults with moderate Parkinson’s, ages 45 to 75, who…

Aspen Neuroscience has completed dosing the first two groups of patients in ASPIRO, an ongoing Phase 1/2a clinical trial that’s testing the safety and tolerability of ANPD001, an investigational cell therapy for Parkinson’s disease. Patients with moderate to severe Parkinson’s who have so far received ANPD001, which uses…

BlueRock Therapeutics said it is progressing its investigational cell therapy, bemdaneprocel, into a Phase 3 clinical trial set to begin in the first half of 2025. The trial, named exPDite-2, will assess the safety and efficacy of the treatment for moderate Parkinson’s disease. This decision comes after positive…

Medtronic’s BrainSense adaptive deep brain stimulation (aDBS) system and electrode identifier have received CE Mark approval in the European Union (EU) and the U.K. for the management of Parkinson’s disease. CE Mark approval indicates that the European Commission, the EU’s regulatory body, considered Medtronic’s system to meet…